ISIS Pharmaceuticals Earns “Outperform” Rating from BMO Capital Markets (ISIS)
ISIS Pharmaceuticals (NASDAQ:ISIS)‘s stock had its “outperform” rating reiterated by analysts at BMO Capital Markets in a research report issued to clients and investors on Thursday. They currently have a $70.00 price objective on the stock. BMO Capital Markets’ target price would suggest a potential upside of 76.86% from the company’s current price.
A number of other analysts have also recently weighed in on ISIS. Analysts at Laidlaw initiated coverage on shares of ISIS Pharmaceuticals in a research note on Tuesday, August 12th. They set a “buy” rating on the stock. Separately, analysts at Laidlow & Co. initiated coverage on shares of ISIS Pharmaceuticals in a research note on Tuesday, August 12th. They set a “buy” rating and a $52.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, August 7th. They now have a $35.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $44.92.
Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) traded up 0.61% on Thursday, hitting $39.82. 2,855,626 shares of the company’s stock traded hands. ISIS Pharmaceuticals has a one year low of $22.25 and a one year high of $62.66. The stock’s 50-day moving average is $32.59 and its 200-day moving average is $36.46. The company’s market cap is $4.688 billion.
ISIS Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.12) by $0.02. The company had revenue of $57.08 million for the quarter, compared to the consensus estimate of $45.60 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. The company’s quarterly revenue was up 49.8% on a year-over-year basis. On average, analysts predict that ISIS Pharmaceuticals will post $-0.75 earnings per share for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.